Skip to main content
. 2016 Oct 19;9:64. doi: 10.1186/s12920-016-0226-1

Fig. 2.

Fig. 2

Overall flow chart of the two-stage analysis strategy. a, de-novo mutation calling and initial assessment of neoplasm contamination by using WES; b, targeted validation and ultra-deep sequencing to assess neoplasm contamination level in each adjacent non-neoplastic tissue. WES: whole exome sequencing; TAS: targeted amplicon sequencing; SNV: single nucleotide variant; VAF: variant allele fraction